A Prospective, Randomized, Double‑Blinded, Vehicle‑ and Placebo-Controlled, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of IDCT in Subjects With Single‑Level, Symptomatic Lumbar Intervertebral Disc Degeneration
Phase of Trial: Phase I/II
Latest Information Update: 10 May 2018
At a glance
- Drugs Injectable-discogenic-cell-therapy-DiscGenics (Primary)
- Indications Intervertebral disc degeneration
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors DiscGenics
- 16 Mar 2018 Planned End Date changed from 1 Nov 2020 to 1 Apr 2021.
- 16 Mar 2018 Planned primary completion date changed from 1 Nov 2019 to 1 Apr 2020.
- 16 Mar 2018 Status changed from not yet recruiting to recruiting.